Area of research
Hepatology · Pharmacology
Research interest
Research interests include Drug-Induced Hepatotoxicity and Protection, Liver Disease Diagnosis and Treatment, Liver Diseases and Immunity, and Liver Disease and Transplantation.
Editorial: The Role of Liver Biopsy in ANA Positive Subjects.
An update on drug-induced liver injury-What's new?
HLA-B*44 Alleles and HLA-DQA1*03:01 as Genetic Risk Factors for Drug-Induced Liver Injury due to Fluoroquinolones.
Drug-induced cholestatic liver diseases.
The Frequency of Drug-Induced Liver Injury Due to Antibiotics Among Hospitalised Patients.
Secondary Sclerosing Cholangitis due to Drugs With a Special Emphasis on Checkpoint Inhibitors.
DILI Is an Important Cause of Hepatocellular and Mixed Liver Injury-A Nationwide Prospective Study on Elevated Liver Enzymes.
Editorial: Cephalosporin-Induced Liver Injury-Interesting but Tricky.
The role of liver biopsy in diagnosing patients with autoimmune hepatitis - it can be acceptable to skip!
Clinically Important Decrease in Liver Stiffness Following Treatment for Hepatitis C: Outcome of the TraP HepC Nationwide Elimination Program.
<i>Helicobacter pylori</i> Across Continents: Contrasts in Epidemiology, Genetics, Clinical Impact, and Management Between East and West.
Characteristics and Neoplastic Progression in Barrett's Esophagus: A Large Population-Based Study from Iceland.
The Association Between Colorectal Cancer and Pharmaceuticals with Emphasis on Low-Dose Aspirin and Anticoagulants
Alcohol-induced pancreatitis and alcohol-related liver disease: Two different phenotypes of alcohol-related harm or related conditions?
Chemoprevention of Colorectal Cancer-With Emphasis on Low-Dose Aspirin and Anticoagulants.
Identification of Distinguishing Features of Drug-Induced Liver Injury and Liver Injury Associated With Sepsis.
Integrative common and rare variant analyses provide insights into the genetic architecture of liver cirrhosis
The Epidemiology of Newly Recognized Causes of Drug-Induced Liver Injury: An Update.
Rebound Acid Hypersecretion after Withdrawal of Long-Term Proton Pump Inhibitor (PPI) Treatment-Are PPIs Addictive?
Hepatocellular Jaundice due to Hydroxycut in Monozygotic Twins.
Hepatotoxicity in inflammatory bowel disease: Immunomodulators, biologics, and beyond.
Reply to: "Distinction of autoimmune hepatitis from drug-induced autoimmune like hepatitis: The answer lies at the interface".
Editorial: Plants against animals.
Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report
A new framework for advancing in drug-induced liver injury research. The Prospective European DILI Registry.
Review article: the safety of anticoagulants and antiplatelet agents in patients with cirrhosis.
Drug-induced liver injury due to nitrofurantoin: Similar clinical features, but different HLA risk alleles in an independent cohort.
Study design for development of novel safety biomarkers of drug-induced liver injury by the translational safety biomarker pipeline (TransBioLine) consortium: a study protocol for a nested case-control study.
Response to: Letter to the Editor by Trinh et al. Drug-induced liver injury registries are important.
Infliximab-induced liver injury: Clinical phenotypes, autoimmunity and the role of corticosteroid treatment.